Study guide

5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy

BCEMP Board Certified Emergency Medicine Pharmacist Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Introduction, Triage, and Resuscitation Fundamentals

1.1 BCEMP Exam Logistics, Content Outlines & Scoring 1.2 Emergency Triage Systems (ESI) & Pre-Hospital Care Coordination 1.3 Resuscitation Pharmacology, Pharmacokinetics & Vascular Access

2 Chapter 2: Cardiac Arrest and Dysrhythmias

2.1 Adult Cardiac Arrest & ACLS Pharmacotherapy Protocols 2.2 Acute Tachyarrhythmias: Narrow- and Wide-Complex Management 2.3 Symptomatic Bradycardia & Vasoactive Chronotropic Support 2.4 Post-Cardiac Arrest Care & Targeted Temperature Management (TTM)

3 Chapter 3: Shock and Hemodynamic Resuscitation

3.1 Sepsis & Septic Shock: Surviving Sepsis Campaign 2026 Resuscitation 3.2 Cardiogenic & Obstructive Shock, Mechanical Circulatory Support & LVADs 3.3 Hypovolemic & Hemorrhagic Shock Fluid Protocols

4 Chapter 4: Airway Management and Rapid Sequence Intubation (RSI)

4.1 Rapid Sequence Intubation (RSI) Process & Pretreatment Agents 4.2 RSI Induction Agents: Pharmacology, Selection & Dosing 4.3 Neuromuscular Blocking Agents & Post-Intubation Analgosedation

5 Chapter 5: Neurocritical Care and Neurologic Emergencies

5.1 Acute Ischemic Stroke: Thrombolysis & Blood Pressure Control 5.2 Intracranial Hemorrhage & Elevated ICP Pharmacotherapy 5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy 5.4 Traumatic Brain Injury & Spinal Cord Emergencies

6 Chapter 6: Acute Coronary Syndromes and Acute Heart Failure

6.1 Acute Coronary Syndromes: STEMI & NSTE-ACS Pharmacotherapy 6.2 Acute Decompensated Heart Failure & Cardiogenic Pulmonary Edema 6.3 Hypertensive Crises: Emergencies, Urgencies & Target Blood Pressure

7 Chapter 7: Pulmonary and Allergic Emergencies

7.1 Acute Pulmonary Embolism: Risk Stratification & Thrombolytic Therapy 7.2 Severe Asthma Exacerbation & COPD Acute Management 7.3 Anaphylaxis & Severe Allergic Reactions: Acute Epinephrine Protocols

8 Chapter 8: Clinical Toxicology: Approach to Poisoning and Common Overdoses

8.1 Approach to the Poisoned Patient: Poison Centers, Toxidromes, Decontamination & Enhanced Elimination 8.2 Acetaminophen Overdose & N-Acetylcysteine Dosing Strategies 8.3 Salicylate Toxicity & Toxic Alcohol Management (Fomepizole) 8.4 Opioid Toxicity & Sedative-Hypnotic/Alcohol Withdrawal Syndromes 8.5 Beta-Blocker & Calcium Channel Blocker Toxicity (HIET, Calcium, Glucagon)

9 Chapter 9: Toxicology: Specialized Poisonings and Antidotes

9.1 Digoxin, Tricyclic Antidepressants & Anticholinergic Toxicity 9.2 Cyanide, Carbon Monoxide & Organophosphate/Cholinergic Toxins 9.3 Snake and Spider Envenomations & Heavy Metal Chelation 9.4 Additional Antidotes: Methemoglobinemia, Isoniazid, Sulfonylureas, Valproate, Sympathomimetics & LAST

10 Chapter 10: Hemostasis, Anticoagulant Reversal, and Hematology

10.1 DOAC & Warfarin Reversal: Specific Reversal Agents & 4F-PCC 10.2 Heparin-Induced Thrombocytopenia (HIT) & Direct Thrombin Inhibitors 10.3 Sickle Cell Vaso-Occlusive Crises & Acute Chest Syndrome

11 Chapter 11: Endocrine, Electrolyte, and Metabolic Emergencies

11.1 Diabetic Ketoacidosis (DKA) & Hyperosmolar Hyperglycemic State (HHS) 11.2 Severe Electrolyte Emergencies: Hyperkalemia & Hyponatremia 11.3 Endocrine Crises: Thyroid Storm, Myxedema Coma & Acute Adrenal Crisis 11.4 Acute Kidney Injury, Dialyzability & Drug Dosing during RRT

12 Chapter 12: Infectious Diseases and Antimicrobial Stewardship

12.1 Severe Community & Hospital-Acquired Infections in the ED 12.2 Skin & Soft Tissue, STI, and Vector-Borne Emergencies 12.3 ED Antimicrobial Stewardship & Rapid Microbiologic Diagnostics

13 Chapter 13: Special Populations: Pediatrics, Trauma, and Obstetrics

13.1 Pediatric Resuscitation, Status Epilepticus & PALS Pharmacotherapy 13.2 Trauma Pharmacotherapy: Massive Transfusion, TXA, Open Fractures, Tetanus & Burns 13.3 Obstetric & Gynecologic Emergencies: Preeclampsia, Eclampsia & PPH

14 Chapter 14: Medication Safety, ED Operations, and Disaster Preparedness

14.1 ED High-Alert Medications, Error Reporting & Technology Safeguards 14.2 ED Workflow, Transitions of Care & Boarding Patient Management 14.3 Mass Casualty Incidents, CBRNE Countermeasures & Strategic Stockpiles

15 Chapter 15: Biostatistics, Study Design, and Literature Evaluation

15.1 Biostatistics & Hypothesis Testing: Power, Errors & Interpretations 15.2 Clinical Study Designs & Measures of Effect 15.3 Literature Evaluation, Clinical Guidelines & Research Conduct in the ED

16 Chapter 16: Medical Devices, Ventilation, and Medication Delivery

16.1 Mechanical Ventilation, Noninvasive Ventilation & High-Flow Oxygen: What the Pharmacist Must Know 16.2 Vascular Access, Enteral Tubes, Drains & Extravasation Management 16.3 Infusion Pumps, Patient-Owned Devices & Medication Delivery Device Counseling

17 Chapter 17: Organ-System Emergencies: GI, GU, Oncology, Neurology, ENT, Pain, and Psychiatry

17.1 Gastrointestinal & Hepatic Emergencies: GI Bleeding, Cirrhosis Complications, Pancreatitis & Vomiting 17.2 Genitourinary Emergencies: UTI & Pyelonephritis, Renal Colic, Urinary Retention, Priapism & Scrotal Infections 17.3 Oncologic, Immunotherapy & Hematologic Emergencies: Febrile Neutropenia, TLS, Hypercalcemia, irAEs, CAR-T, Hemophilia & TTP 17.4 Headache & Neuromuscular Emergencies: Migraine, Cluster, Myasthenic Crisis, Guillain-Barré & Bell's Palsy 17.5 Ophthalmologic, ENT & Dental Emergencies: Eye Injuries, Angle Closure, Angioedema, Epistaxis, Ear & Throat Infections and Dental Pain 17.6 Acute Pain Management & Procedural Sedation and Analgesia in the ED 17.7 Psychiatric Emergencies: Severe Agitation, Serotonin Syndrome, NMS, Lithium Toxicity & Psychotropic Overdose

18 Chapter 18: Special Populations, Medication Access, and Professional Practice

18.1 Pharmacogenomics, Adverse Drug Events & High-Risk Drug Interactions in Emergency Care 18.2 Special Populations: Older Adults, Extremes of Weight, Pregnancy & Lactation, and Immunocompromised Patients 18.3 Social Determinants of Health, Health Literacy & Medication Access at ED Discharge 18.4 Healthcare Regulations & Standards: FDA, REMS, Bar Coding, DEA, CMS, EMTALA, The Joint Commission, NIOSH & USP 18.5 Formulary & Inventory Management, Drug Shortages, Antidote Stocking & Clinical Decision Support 18.6 Quality Improvement, Practice Standards & Interprofessional Collaboration (Protocols, Teamwork & Debriefing)

5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy

Key Takeaways Explain This Topic AI

Status epilepticus is defined operationally as >=5 minutes of continuous convulsive seizure activity (t1), with permanent neuronal necrosis and pharmacoresistance occurring at >=30 minutes (t2) driven by GABA-A receptor internalization and NMDA receptor upregulation.

Phase 1 emergent therapy requires prompt benzodiazepine administration: IV lorazepam (0.1 mg/kg or 4 mg IV push), IM midazolam (10 mg IM for >40 kg; supported by the RAMPART trial when IV access is absent), or IV diazepam (0.15 to 0.2 mg/kg).

Phase 2 established status epilepticus is guided by the landmark ESETT trial, demonstrating equivalent ~50% efficacy across IV levetiracetam (60 mg/kg, max 4500 mg), IV fosphenytoin (20 mg PE/kg, max 1500 mg PE at 150 mg PE/min), and IV valproate sodium (40 mg/kg, max 3000 mg).

Phase 3 refractory status epilepticus necessitates endotracheal intubation, continuous EEG monitoring targeting burst suppression, and continuous anesthetic infusions of propofol (monitor for PRIS), midazolam, or ketamine (NMDA antagonism).

Last updated: October 2026

5.3 Status Epilepticus: Tiered Emergent Anticonvulsant Therapy

Note

Independent BCEMP study resource provided by ExamFinch. Content is organized around neurocritical care and emergency pharmacotherapy principles.

Status epilepticus (SE) is a life-threatening neurologic emergency requiring immediate, systematic pharmacotherapeutic escalation. Convulsive status epilepticus that fails to terminate spontaneously produces severe systemic derangements—including hyperpyrexia, severe lactic and metabolic acidosis, rhabdomyolysis, hyperkalemia, pulmonary aspiration, and autonomic instability—alongside progressive, irreversible neuronal excitotoxicity. Emergency medicine pharmacists play an indispensable role in ensuring weight-appropriate dosing, minimizing preparation delays, monitoring line compatibility, and guiding the transition between sequential therapy phases.

Operational Definitions & The t 1 / t 2 t_1 / t_2 t 1 ​ / t 2 ​ Time Framework

The Neurocritical Care Society (NCS) and the International League Against Epilepsy (ILAE) define status epilepticus using a dual-time-point framework ( t 1 t_1 t 1 ​ and t 2 t_2 t 2 ​ ):

Time Point 1 ( t 1 = 5 minutes t_1 = 5\text{ minutes} t 1 ​ = 5 minutes for generalized convulsive SE) :

Represents the operational definition at which spontaneous seizure termination is highly improbable and emergent pharmacotherapy must be initiated immediately.

While historically defined as continuous seizure activity lasting 30 minutes, clinical data demonstrate that normal generalized tonic-clonic seizures spontaneously terminate within 2 to 3 minutes. Any seizure persisting beyond 5 minutes must be aggressively treated as status epilepticus.

Time Point 2 ( t 2 = 30 minutes t_2 = 30\text{ minutes} t 2 ​ = 30 minutes for generalized convulsive SE) :

Represents the threshold beyond which continuous electrographic seizure activity causes permanent, irreversible neuronal injury , profound cerebral metabolic exhaustion, and long-term functional impairment.

Molecular Receptor Trafficking & Pharmacoresistance

The transition from early status epilepticus to refractory status epilepticus is driven by rapid, activity-dependent receptor trafficking at neuronal synapses:

GABA-A Receptor Internalization : Within minutes of persistent seizure activity, inhibitory postsynaptic GABA-A receptors undergo clathrin-dependent endocytosis and intracellular dephosphorylation. Surface inhibitory GABA-A receptors decrease by up to 50% to 70%, rendering the brain progressively resistant to benzodiazepines .

NMDA and AMPA Receptor Externalization : Concurrently, excitatory glutamatergic NMDA and AMPA receptors are recruited and inserted into the postsynaptic membrane. This creates a severe mismatch: massive glutamatergic excitatory drive paired with depleted GABAergic inhibitory tone.

Important

Because GABA-A receptors rapidly internalize as seizure duration lengthens, benzodiazepines must be administered early at full guideline-directed doses . Underdosing benzodiazepines is the most frequent clinical error in status epilepticus management and directly increases the risk of refractory status.

Phase 1: Emergent Initial Therapy (0 to 5 Minutes)

Benzodiazepines are the uncontested first-line therapy for early status epilepticus, enhancing inhibitory chloride currents by increasing the opening frequency of remaining surface GABA-A receptors.

1. Intravenous Lorazepam (Ativan)

Dosing : 0.1 mg/kg IV push (typical adult dose 4 mg ), administered at a rate not exceeding 2 mg/min 2\text{ mg/min} 2 mg/min . May repeat once after 5 to 10 minutes if seizures persist.

Pharmacokinetics : Intermediate lipid solubility. Slower brain entry than diazepam (onset 2 to 3 minutes), but exhibits minimal redistribution into peripheral adipose tissue, resulting in a prolonged effective CNS duration of action ( 4 to 6 hours ).

Vehicle Toxicity : Formulated with propylene glycol (80% v/v); prolonged high-dose infusions can cause hyperosmolality, lactic acidosis, and acute renal failure (reserved for bolus dosing).

2. Intramuscular Midazolam (Versed) & The RAMPART Trial

Dosing : 10 mg IM for patients weighing > 40 kg >40\text{ kg} > 40 kg ; 5 mg IM for patients weighing 13 to 40 kg 13\text{ to }40\text{ kg} 13 to 40 kg . Administer into the anterolateral thigh.

Pharmacokinetics : Water-soluble at the formulation vial pH (pH 3.5) due to an open imidazole ring. Upon intramuscular injection at physiological tissue pH (pH 7.4), the ring closes, rendering midazolam highly lipophilic and producing rapid systemic and CNS absorption.

Evidence (The RAMPART Trial) : A landmark, double-blind randomized clinical trial (NEJM 2012) comparing prehospital IM midazolam (via autoinjector) against IV lorazepam. IM midazolam was non-inferior and clinically superior in real-world time-to-seizure-cessation: 73.4% of patients receiving IM midazolam arrived at the ED with terminated seizures compared to 63.4% receiving IV lorazepam (p<0.001). This operational advantage occurred because eliminating the delay required to establish intravenous access allowed significantly earlier drug administration (1.2 min vs. 4.8 min).

3. Intravenous Diazepam (Valium)

Dosing : 0.15 to 0.2 mg/kg IV push (typical dose 10 mg ), administered at 5 mg/min 5\text{ mg/min} 5 mg/min . May repeat once in 5 minutes.

Pharmacokinetics : Highly lipophilic; crosses the blood-brain barrier within 1 minute. However, it rapidly redistributes from the CNS into peripheral fat compartments (distribution half-life ~15 to 30 minutes), resulting in a brief clinical duration of anticonvulsant activity and high rates of seizure recurrence unless followed immediately by a long-acting ASM.

Non-Intravenous Alternatives

When neither IV nor IM access is immediately feasible: Rectal diazepam gel (0.2 to 0.5 mg/kg, max 20 mg) or Intranasal midazolam (0.2 mg/kg, max 10 mg; divided between both nares using a mucosal atomization device [MAD]).

Phase 2: Urgent Control Therapy (5 to 20 Minutes) — Established Status Epilepticus

Phase 2 therapy is indicated when seizures persist despite adequate first-line benzodiazepine administration. Non-sedating intravenous antiseizure medications (ASMs) are initiated immediately.

Loading diagram...

The Landmark ESETT Trial (2019)

The Established Status Epilepticus Treatment Trial (ESETT) was a multicenter, randomized, blinded, comparative-effectiveness trial (NEJM 2019) evaluating 384 children and adults with benzodiazepine-refractory status epilepticus randomized to one of three IV regimens:

Levetiracetam : 60 mg/kg IV (maximum 4,500 mg) infused over 10 minutes.

Fosphenytoin : 20 mg PE/kg IV (maximum 1,500 mg PE) infused at 150 mg PE/min.

Sodium Valproate : 40 mg/kg IV (maximum 3,000 mg) infused over 10 minutes.

Primary Findings :

Seizure cessation and improved responsiveness at 60 minutes occurred in 47% of levetiracetam patients, 45% of fosphenytoin patients, and 46% of valproate patients (differences were statistically non-significant).

Safety profiles (incidence of endotracheal intubation, life-threatening hypotension, cardiac arrhythmias, and mortality) were statistically equivalent across all three arms.

Guideline Conclusion : All three medications are endorsed as equivalent first-line options for Phase 2 status epilepticus .

Detailed Pharmacology of Phase 2 Agents

Levetiracetam (Keppra) :

Mechanism : Binds to synaptic vesicle protein 2A (SV2A), modulating synaptic exocytosis of neurotransmitters.

Dosing : 60 mg/kg IV (maximum 4,500 mg ) infused in 100 mL 0.9% NaCl over 10 minutes.

Clinical Pearls : Minimal hepatic metabolism; cleared renally. Complete lack of cytochrome P450 drug interactions. Causes zero cardiac dysrhythmias or hypotension; does not require ECG or hemodynamic telemetry during infusion.

Fosphenytoin (Cerebyx) :

Mechanism : Water-soluble phosphate ester prodrug of phenytoin that selectively blocks voltage-gated sodium channels in inactivated states.

Dosing & Units : 20 mg Phenytoin Sodium Equivalents (PE)/kg IV (maximum 1,500 mg PE ). Infused at a rate up to 150 mg PE/min (administered over ~10 minutes).

Fosphenytoin vs. Phenytoin : Phenytoin injection uses a vehicle of 40% propylene glycol and 10% ethanol at pH about 12, causing severe phlebitis, tissue necrosis upon extravasation ("purple glove syndrome"), and severe vehicle-induced bradycardia and hypotension (maximum infusion rate only 50 mg/min). Fosphenytoin dissolves freely in aqueous saline at pH 8.6, eliminating propylene glycol toxicity and allowing 3x faster infusion rates without purple glove risk. Still requires blood pressure and ECG telemetry during infusion due to sodium-channel blockade.

Valproate Sodium (Depacon) :

Mechanism : Increases brain GABA synthesis, inhibits GABA degradation (GABA transaminase), and blocks T-type calcium and voltage-gated sodium channels.

Dosing : 40 mg/kg IV (maximum 3,000 mg ) infused over 10 minutes.

Contraindications : Acute liver failure, urea cycle disorders (precipitates catastrophic hyperammonemic encephalopathy), and mitochondrial disorders (mutations in mitochondrial DNA polymerase gamma [POLG]). Avoid it when possible in pregnancy and in people who could become pregnant (neural tube defects and other teratogenicity), although it may still be used in a life-threatening emergency when alternatives fail.

Lacosamide (Vimpat) :

Mechanism : Selectively enhances slow inactivation of voltage-gated sodium channels without affecting fast inactivation.

Dosing : 200 to 400 mg IV bolus infused over 3 to 5 minutes.

Clinical Pearls : Second-tier alternative; causes dose-dependent PR interval prolongation. Avoid in second- or third-degree heart block or severe conduction disease.

Phase 3: Refractory Status Epilepticus (RSE, >20 to 40 Minutes)

Refractory status epilepticus (RSE) is defined as continuous or recurrent seizure activity failing to terminate despite full, weight-appropriate doses of a first-line benzodiazepine and a second-line non-sedating ASM.

Clinical Management Mandates

Endotracheal Intubation & Mechanical Ventilation : Mandatory to protect the airway and control oxygenation/ventilation.

Continuous Video-Electroencephalography (cEEG) : Mandatory because up to 50% of RSE patients develop non-convulsive status epilepticus (NCSE) , where motor convulsions cease due to neuromuscular exhaustion but catastrophic electrographic seizure activity persists in the cerebral cortex.

Therapeutic Endpoint : Titrate continuous anesthetic infusions to achieve electrographic seizure cessation or burst suppression (e.g., 10 to 15 seconds of electrical suppression between periodic bursts) maintained for 24 to 48 hours before attempting gradual taper.

Continuous Anesthetic Infusions

Propofol (Diprivan) :

Mechanism : Potent GABA-A receptor agonist and antagonist at glutamatergic NMDA receptors.

Dosing : Loading bolus of 1 to 2 mg/kg IV over 5 minutes, followed by a continuous infusion of 20 to 100 mcg/kg/min (1.2 to 6 mg/kg/h).

Propofol Infusion Syndrome (PRIS) : A labeled warning (not a boxed warning) for prolonged (>48 hours) or high-dose (>4 to 5 mg/kg/h or >67 to 83 mcg/kg/min) infusions. Features refractory lactic acidosis, rhabdomyolysis (massive CK elevation), hyperkalemia, hypertriglyceridemia, hepatomegaly, renal failure, and Brugada-like ST elevations or fatal cardiogenic shock. Monitor lactate, CK, serum potassium, and triglycerides every 12 to 24 hours.

Midazolam :

Dosing : Loading bolus of 0.2 mg/kg IV , followed by continuous infusion of 0.05 to 2 mg/kg/h .

Clinical Pearls : Highly effective acute anticonvulsant, but suffers from rapid tachyphylaxis within 24 to 48 hours secondary to GABA-A receptor desensitization. The active metabolite (1-hydroxymidazolam) accumulates in renal failure, causing prolonged post-cessation sedation.

Ketamine :

Mechanism : Non-competitive open-channel blocker of the NMDA receptor . Counteracts the molecular pathophysiological upregulation of excitatory NMDA receptors in late status epilepticus.

Dosing : Loading bolus of 1 to 3 mg/kg IV , followed by continuous infusion of 0.5 to 5 mg/kg/h .

Clinical Pearls : Preserves systemic vascular resistance and cardiac output; avoids the profound vasopressor requirements of propofol and barbiturates. Highly effective in super-refractory SE.

Pentobarbital / Thiopental (Barbiturates) :

Mechanism : Directly opens GABA-A chloride channels independently of GABA at high concentrations and inhibits AMPA receptors.

Dosing : Pentobarbital loading bolus 5 mg/kg IV at 50 mg/min 50\text{ mg/min} 50 mg/min , followed by continuous infusion of 1 to 5 mg/kg/h .

Clinical Pearls : Achieves the highest rates of burst suppression, but produces profound myocardial depression, systemic vasodilation (routinely requiring multiple concurrent vasopressors), paralytic ileus, prolonged terminal half-life (20 to 50 hours), and high secondary infection rates.

Status Epilepticus Pharmacotherapy Reference Matrix

Phase & Tier First-Line Agents Evidence-Based Dosing Primary Mechanism Critical Clinical Pearls & Pitfalls

Phase 1: Emergent (0–5 min) IV Lorazepam 0.1 mg/kg IV (max 4 mg) GABA-A receptor allosteric agonist Slow IV push over 2 min; duration 4–6h. Repeat once in 5–10 min if seizing.

Phase 1: Emergent (0–5 min) IM Midazolam 10 mg IM (>40 kg), 5 mg (13–40 kg) GABA-A receptor allosteric agonist Preferred over IV lorazepam when IV access is delayed (RAMPART trial).

Phase 2: Urgent (5–20 min) IV Levetiracetam 60 mg/kg IV over 10 min (max 4500 mg) Synaptic vesicle protein 2A (SV2A) ligand Equivalent efficacy to fosphenytoin/valproate (ESETT). Cleared renally; zero drug interactions.

Phase 2: Urgent (5–20 min) IV Fosphenytoin 20 mg PE/kg IV at 150 mg PE/min (max 1500) Voltage-gated Na+ channel blocker Aqueous prodrug; 3x faster than phenytoin without purple glove risk. ECG telemetry required.

Phase 2: Urgent (5–20 min) IV Valproate 40 mg/kg IV over 10 min (max 3000 mg) Enhances GABA, blocks Na+/Ca2+ channels Equivalent in ESETT. Avoid in acute hepatic failure, urea cycle disorders, and pregnancy.

Phase 3: Refractory (>20–40 min) IV Propofol 1–2 mg/kg bolus, then 20–100 mcg/kg/min GABA-A agonist / NMDA modulator Intubation and cEEG required. Monitor for PRIS (CK, triglycerides, lactate, K+).

Phase 3: Refractory (>20–40 min) IV Ketamine 1–3 mg/kg bolus, then 0.5–5 mg/kg/h Non-competitive NMDA receptor blocker Directly targets upregulated NMDA receptors. Supports hemodynamics in refractory shock.